stay updated with our newsletter

Larch Arabinogalactan and Immune Response

Influenza A

In 2013, a study, Immunomodulatory Effects of ResistAid™: A Randomized, Double-Blind, Placebo-Controlled, Multidose Study, evaluated the ability of a proprietary arabinogalactan extract from the larch tree (ResistAid™, Lonza Ltd., Basel, Switzerland) to change the immune response in healthy adults to a standardized antigenic challenge of tetanus and influenza vaccines in a dose-dependent manner compared to placebo. As it is flu season, Today’s Practitioner is revisiting the study and the subject with an interview with Bryan Rodriguez, Global Products Manager, of Lonza, makers of Resist Aid. Download the full study at the end of this article.

JOIN OUR MAILING LIST

Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.